Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PITRESSIN TANNATE vs DIAPID
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Pitressin Tannate is a synthetic form of vasopressin (antidiuretic hormone) that acts on V2 receptors in the renal collecting ducts to increase water reabsorption, and on V1 receptors to cause vasoconstriction.
Diapid (lypressin) is a synthetic analog of vasopressin that acts as an antidiuretic by increasing water reabsorption in the renal collecting ducts via V2 receptor activation. It also has mild vasopressor activity via V1 receptor stimulation.
Diabetes insipidus (central),Nocturnal enuresis (off-label),Variceal bleeding (off-label)
Diabetes insipidus (central),Nocturnal enuresis (off-label)
0.5-1 m L (5-10 units) intramuscularly or subcutaneously every 24-48 hours as needed for diabetes insipidus.
Intravenous bolus of 20 mg followed by 20-40 mg every 2-4 hours as needed. Maximum single dose: 80 mg.
Terminal elimination half-life approximately 15 minutes (range 10–20 minutes). Clinically, due to rapid clearance, effects are short-lived; continuous infusion or depot formulations are required for sustained effect.
Terminal elimination half-life is 1.5-3 hours; clinically significant in patients with renal impairment, requiring dose adjustment
Metabolized primarily by the liver and kidneys via peptidases, with a half-life of about 10-20 minutes for vasopressin itself; the tannate formulation prolongs absorption.
Lypressin is rapidly metabolized by peptidases in the liver and kidneys, with a half-life of approximately 15 minutes.
Primarily renal: >95% of administered dose excreted unchanged in urine within 24 hours. Biliary/fecal elimination negligible (<5%).
Primarily renal excretion as unchanged drug (80-90%); minor biliary/fecal elimination (<10%)
Negligible (<1%); mainly bound to plasma proteins primarily vasopressin-binding proteins and albumin, but binding is not clinically significant.
20-30% bound to plasma proteins
Approximately 0.1 L/kg (range 0.08–0.12 L/kg). This low Vd indicates minimal tissue distribution, consistent with its predominant plasma volume confinement and renal clearance.
0.6-0.8 L/kg; distributes primarily in extracellular fluid
Intramuscular oil suspension: nearly 100% but with slow release. Subcutaneous: approximately 10–15% due to hydrolysis at injection site. Oral: negligible (<1%) due to enzymatic degradation.
100% by intravenous route; Not bioavailable orally
Not significantly renally excreted; no specific dose adjustment recommended based on GFR.
No adjustment required for GFR >30 m L/min. For GFR 10-30 m L/min: reduce dose by 50%. For GFR <10 m L/min: avoid use.
No specific guidelines; use with caution in hepatic impairment due to potential fluid imbalance.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%. Child-Pugh C: contraindicated.
0.1-0.3 m L (1-3 units) intramuscularly or subcutaneously, with dose adjusted based on response; monitor urine output and serum sodium.
0.2 mg/kg intravenously, repeat every 2 hours as needed. Maximum dose: 10 mg.
Start at lower end of dosing range (0.5 m L initially) due to increased risk of electrolyte disturbances and comorbid conditions; monitor serum sodium and fluid status closely.
Initial dose of 10 mg intravenously, titrate cautiously due to increased sensitivity. Maximum single dose: 40 mg.
None.
None.
Hyponatremia and water intoxication; cardiac effects including arrhythmias and ischemia; mesenteric ischemia; hypersensitivity reactions; use with caution in patients with coronary artery disease, hypertension, or renal impairment.
Monitor fluid and electrolyte balance to avoid water intoxication and hyponatremia.,Use with caution in patients with coronary artery disease, hypertension, or renal impairment.,May cause anaphylaxis or hypersensitivity reactions.
Hypersensitivity to vasopressin or components; anuria; chronic nephritis with nitrogen retention; cardiovascular disease (ischemic heart disease, advanced atherosclerosis, coronary thrombosis).
Hypersensitivity to lypressin or any component,Severe renal impairment (anuria),Chronic nephritis with nitrogen retention
Avoid excessive fluid intake beyond thirst to prevent water intoxication. Limit alcohol, which can inhibit vasopressin release and reduce drug efficacy. No specific food restrictions.
No significant food interactions. However, avoid excessive water intake and alcohol, which can affect ADH secretion.
PITRESSIN TANNATE (vasopressin tannate) is classified as FDA Pregnancy Category C. In animal studies, vasopressin has been associated with decreased fetal weight and delayed ossification at high doses. There are no adequate and well-controlled studies in pregnant women. The drug should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Vasopressin may cause uterine contractions and decrease placental perfusion, potentially leading to fetal hypoxia or distress, particularly in the third trimester.
Diapide is contraindicated in pregnancy due to known teratogenic effects. First trimester exposure is associated with increased risk of congenital malformations, particularly cardiovascular and neural tube defects. Second and third trimester exposure may cause fetal hyperinsulinemia, macrosomia, and neonatal hypoglycemia.
It is unknown whether vasopressin is excreted in human breast milk. Due to its high molecular weight (tannate salt) and poor oral bioavailability, significant absorption by a nursing infant is unlikely. However, caution is advised. No M/P ratio is available.
Excretion into breast milk is unknown; however, due to potential for adverse effects in the nursing infant (e.g., hypoglycemia), breastfeeding is not recommended during therapy. M/P ratio: not determined.
No specific dose adjustments are established for pregnancy. However, because of increased plasma volume and renal clearance during pregnancy, lower serum concentrations may occur. Individualize dosing based on clinical response and avoidance of adverse effects such as hyponatremia and hypertension. Use the lowest effective dose.
No safe dose established in pregnancy. If use is unavoidable during pregnancy, dose adjustment is not recommended due to teratogenicity; alternative therapy should be employed.
Pitressin Tannate is an aqueous suspension of vasopressin for intramuscular injection used for diabetes insipidus. Must be warmed and shaken vigorously before administration to ensure uniform suspension. Inject deeply IM into a large muscle; do not administer IV or subcutaneously. Onset is within 1-2 hours, duration 24-72 hours. Monitor for signs of water intoxication (headache, confusion, seizures) due to antidiuretic effect. Caution in coronary artery disease, hypertension, and renal impairment. Discontinue if abdominal cramps or nausea occur. Not for use in chronic nephrogenic diabetes insipidus.
Diapid (desmopressin) is used for central diabetes insipidus and nocturnal enuresis. Monitor for hyponatremia, especially in elderly or patients with fluid/electrolyte imbalance. Avoid overhydration. Intranasal formulation may cause rhinitis or epistaxis.
This medication is given as an injection into a muscle, usually every 1-3 days as prescribed.,Do not inject into a vein or under the skin; only into a muscle (buttock or thigh).,Warm the vial in your hands and shake it well just before use to mix the suspension evenly.,Drink only enough fluid to satisfy thirst; excessive fluid intake can lead to water intoxication.,Report any signs of water intoxication: severe headache, confusion, drowsiness, seizures, or difficulty breathing.,Avoid alcohol, which can interfere with the drug's effect and increase urine output.,Store the vial at room temperature away from light and do not freeze.,Monitor urine output and notify your doctor if it does not decrease or if side effects occur.
Use exactly as prescribed; do not exceed dose to avoid water intoxication.,Limit fluid intake to prevent hyponatremia (symptoms: headache, nausea, confusion).,For intranasal spray, gentle priming and alternating nostrils each dose.,Report signs of low sodium: severe headache, vomiting, muscle cramps, drowsiness.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PITRESSIN TANNATE vs DIAPID, answered by our medical review team.
PITRESSIN TANNATE is a Antidiuretic Hormone Analog that works by Pitressin Tannate is a synthetic form of vasopressin (antidiuretic hormone) that acts on V2 receptors in the renal collecting ducts to increase water reabsorption, and on V1 receptors to cause vasoconstriction.. DIAPID is a Antidiuretic Hormone Analog that works by Diapid (lypressin) is a synthetic analog of vasopressin that acts as an antidiuretic by increasing water reabsorption in the renal collecting ducts via V2 receptor activation. It also has mild vasopressor activity via V1 receptor stimulation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PITRESSIN TANNATE and DIAPID depend on the specific clinical indication. These are both Antidiuretic Hormone Analog agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PITRESSIN TANNATE is: 0.5-1 m L (5-10 units) intramuscularly or subcutaneously every 24-48 hours as needed for diabetes insipidus.. The standard adult dose of DIAPID is: Intravenous bolus of 20 mg followed by 20-40 mg every 2-4 hours as needed. Maximum single dose: 80 mg.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PITRESSIN TANNATE and DIAPID in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PITRESSIN TANNATE is classified as Category C. PITRESSIN TANNATE (vasopressin tannate) is classified as FDA Pregnancy Category C. In animal studies, vasopressin has been associated with decreased fetal weight and delayed ossifi. DIAPID is classified as Category C. Diapide is contraindicated in pregnancy due to known teratogenic effects. First trimester exposure is associated with increased risk of congenital malformations, particularly cardi. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.